Management Team

  • Dave Marver, CEO

    Dave Marver

    Chief Executive Officer

    Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles.
  • John Murphy, PhD, CTO

    John Murphy, PhD

    Chief Technology Officer

    John Murphy has over 25 years of experience driving the development of medical implants and neurostimulation devices at LivaNova, Abbott, and Medtronic. His leadership expertise spans the continuum of R&D, with a focus on consumer-centric design, IP generation, and agile processes. Prior to joining ONWARD in 2020, John was the Chief Technology Officer of LivaNova Neuromodulation. He holds a BS in Electrical Engineering from the University of North Carolina at Charlotte and a PhD in Production Systems and Robotics from the Swiss Federal Institute of Technology (EPFL).
  • Grégoire Courtine, PhD, CSO

    Grégoire Courtine, PhD

    Chief Scientific Officer

    Prof. Grégoire Courtine is the co-founder of ONWARD and its Chief Scientific Officer as well as a Non-Executive Director. His ground-breaking research in neuroscience has been recognized by several prestigious prizes, including the Rolex Award, the Schellenberg Research Prize and the Chancellor’s Award of the University of California. Grégoire is a full professor of neuroscience and neurotechnology at the Swiss Federal Institute of Technology (EPFL) and Director of NeuroRestore, a research center at EPFL and the University Hospital of Lausanne that develops innovative therapies using neurostimulation and other approaches. He holds a PhD in Neurosciences from INSERM, Paris, and a PhD in Medicine from the University of Pavia, Italy.
  • Lara Smith Weber, CFO

    Lara Smith Weber

    Chief Financial Officer

    Lara Smith Weber brings over 25 years of finance, accounting, and strategy experience with life science companies in the United States and Europe. She most recently served as CFO and Head of Commercial Financial Planning and Analysis for MorphoSys, Inc., based in Boston, USA. Prior to that, Lara held various finance leadership roles at MorphoSys AG, based in Munich, Germany. Her roles included Senior VP, Head of Controlling and Corporate Finance, where she led a US$239M NASDAQ IPO in 2018. Previously, Lara spent 7 years at Telefonica Germany in a variety of finance leadership positions and worked for consulting firm, Booz Allen Hamilton, in Zurich, Switzerland. Lara earned a BA in German Studies and both a BS and M.Sc. in Electrical Engineering from Stanford University in Palo Alto, USA. She also earned an MBA from IMD in Lausanne, Switzerland.

  • Vincent Delattre, PhD,  VP Business Development

    Vincent Delattre, PhD

    Vice President, Business Development

    Vincent Delattre co-founded ONWARD in 2014 and currently oversees the company’s extensive IP portfolio and business development activities. Vincent combines expertise in science and business management: he has led pioneering research on electrical stimulation and neural circuit reorganisation and has been recognized by several business prizes, including Hello Tomorrow, Venture Best Business Idea, and the Wellcome Trust Award. He previously served as the company’s CEO and Chief Technology Officer. Vincent holds a PhD in Neurosciences from the Swiss Federal Institute of Technology (EPFL), Lausanne.
  • Hendrik Lambert, PhD,  VP Clinical & Regulatory

    Hendrik Lambert, PhD

    Vice-President, Clinical & Regulatory

    Hendrik Lambert has over 20 years of experience in leading clinical and regulatory strategies for high-risk (Class III) medical devices in both Europe and the US, from initial design to market approval. Before joining ONWARD in 2015, Hendrik was Vice President for Clinical and Regulatory Affairs at Endosense, a Geneva-based medtech company developing innovative products for the cardiology market, which was acquired by St. Jude Medical. He holds a PhD in Biomedical Engineering from the University of Ghent, Belgium.
  • David Harari, Vice President, US Clinical and Regulatory

    David Harari

    Vice President, US Clinical and Regulatory

    David Harari is a talented scientific leader with 30 years of experience in the clinical and regulatory management of medical devices, from initial concept to commercialization. Before joining ONWARD in 2019 to lead its US affiliate, David held senior positions in clinical affairs with Guidant, Boston Scientific, Endosense, St Jude Medical, and Vytronus Inc. He holds a BS in Engineering Sciences and Biomedical Engineering from the University of Michigan.
  • Rano Burkhanova Global HR Director

    Rano Burkhanova

    Global HR Director

    Rano Burkhanova is an accomplished talent development executive with 15 years of experience with multinational companies in the US and the Netherlands. Before joining ONWARD in 2020, Rano managed leadership development, gender diversity, and engagement programs for Danone Nutrition, Elsevier, and Medtronic. She holds an MA in human Resources Management from Cornell University and an MBA from the Quantic School of Science and Technology.
  • Andy Dolan

    Andy Dolan

    Vice President, Marketing

    Andy Dolan has 20 years of experience in marketing, business development, and organizational leadership for medical device companies, both private and public. Before joining ONWARD in 2021, Andy held senior roles in sales and marketing at ReWalk Robotics, Boston Scientific, Johnson & Johnson and Integra LifeSciences. He holds an MBA from the University of Massachusetts and a graduate certificate in bioengineering from Tufts University. He also serves as a United States Navy Reserve Public Affairs Officer.
  • Zouhir Mechta

    Zouhir Mechta

    Vice President, Operations

    Zouhir Mechta brings over 20 years of Operations experience for industry-leading companies such as Johnson & Johnson, Dentsply Sirona, and Nestlé. He previously served as Vice President of Manufacturing and Supply Chain for Dentsply Sirona, with responsibility for the US, EMEA, and Switzerland and management of multiple facilities with over 1,200 staff.  Zouhir also has experience with scale-up company operations and has overseen ERP installations, established manufacturing systems, and built procurement and customer service capabilities. Zouhir earned a master’s degree in Process Management from University of Technology Belfort-Montbéliard and a bachelor’s degree in Mechanical Engineering from the Technology Institute F. Buisson. He is also a certified Lean Six-Sigma Black Belt.

Board Members

  • Executive Chair

    Jan Ohrstrom

    Board Chair

    Jan Ohrstrom is Chair of the Board and Non-Executive Director of ONWARD since 2016. He has over 30 years of experience in the medical technology and pharmaceutical industries, and has a proven track record driving successful product approvals, private financings, and IPOs. Jan has held senior management roles at NovoNordisk, ProFibrix BV and ZymoGenetics, among others. He is currently CEO of VarmX BV, a company specializing in blood clotting agents, and is chairman of Blaze Bioscience Inc. Jan holds an MD from the University of Copenhagen.
  • John de Koning LSP

    John de Koning

    Non-Executive Director

    John de Koning is a Non-Executive Director of ONWARD since 2016. He is a General Partner at LSP, one of the largest European investment firms providing financing for life sciences and health care companies. Since joining the LSP in 2006, John has led some of its most successful investments and served on the board of several companies, including argenx, Merus, and Prosensa. John holds an MS in Molecular Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University Rotterdam.
  • Regina Hodits

    Regina Hodits

    Non-Executive Director

    Regina Hodits is a Non-Executive Director of ONWARD since 2019. She has over 20 years of experience in venture capital and is a managing partner at Wellington Partners Life Science Venture Capital Consulting GmbH, focusing on early-stage and growth investments. Before joining Wellington, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was a founding investor in Bicycle Therapeutics, F-star and JenaValve, and currently serves on the boards of Ayoxyya, Carisma, Sidekick, SNIPR Biome, and Stipe. Regina holds PhD in Biochemistry from the Technical University of Vienna.
  • Kristina Dziekan

    Kristina Dziekan

    Non-Executive Director

    Kristina Dziekan is a Non-Executive Director of ONWARD since 2022. She is Head of Market Access, Government Affairs and Tendering for Alcon’s Surgical Division in Europe. Previous to her experience at Alcon, she served as Senior Global Reimbursement and Health Economics Director for Medtronic Neuromodulation and Health Outcomes Manager for GlaxoSmithKline in the UK and parts of Asia. Ms. Dziekan has an MSc in Health Policy, Planning, and Financing from the London School of Economics, an MA in International Economics and European Studies from Johns Hopkins University, a BA in Philosophy, Politics, and Economics from Oxford University and a Vordiplom in Business Administration and Economics from Georg August University.
  • Ian Curtis

    Ian Curtis

    Non-Executive Director

    Ian Curtis is a Non-Executive Director of ONWARD since 2019. As the father of a young woman living with SCI, Ian is passionate about advancing research and treatment for SCI. He is a member of the board of the Christopher and Dana Reeve Foundation, the International Spinal Research Trust, and the Neurokinex Charitable Trust, which operates activity-based rehabilitation clinics in the UK. Ian holds a BA in History from Durham University and is a member of the Institute of Chartered Accountants in England and Wales.
  • Fred Colen

    Fred Colen

    Non-Executive Director

    Fred Colen is a Non-Executive Director of ONWARD since 2017. With over 40 years of experience in the medical device industry, Fred has a track record in building strong organizations to bring new technology to market. Fred is President and CEO of Neovasc Inc., a Canadian publicly traded company developing products for the cardiovascular marketplace. Previously, he held senior executive roles at Boston Scientific and St Jude Medical. He holds Master’s degrees in Electrical Engineering and Medical Technology from RWTH Aachen University, Germany.
  • Vivian

    Vivian Riefberg

    Non-Executive Director

    Vivian Riefberg is a Non-Executive Director of ONWARD since 2022. She was formerly a senior partner with McKinsey & Company, where she led the Public Sector Practice for the Americas and was co-leader of the U.S. Health Care practice. Vivian is a Professor at University of Virginia’s Darden School of Business. She previously served on the U.S. National Institutes of Health (NIH) Clinical Center Board of Governors and on the NIH Advisory Board for Clinical Research. Vivian currently serves on the boards of Signify Health, K Health, Lightrock and Johns Hopkins Medicine. She holds a B.A., magna cum laude in history from Harvard-Radcliffe College and an M.B.A. with distinction from Harvard Business School.
  • Dave Marver, CEO

    Dave Marver

    Chief Executive Officer

    Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles.
  • Grégoire Courtine, PhD, CSO

    Grégoire Courtine, PhD

    Chief Scientific Officer

    Prof. Grégoire Courtine is the co-founder of ONWARD and its Chief Scientific Officer as well as a Non-Executive Director. His ground-breaking research in neuroscience has been recognized by several prestigious prizes, including the Rolex Award, the Schellenberg Research Prize and the Chancellor’s Award of the University of California. Grégoire is a full professor of neuroscience and neurotechnology at the Swiss Federal Institute of Technology (EPFL) and Director of NeuroRestore, a research center at EPFL and the University Hospital of Lausanne that develops innovative therapies using neurostimulation and other approaches. He holds a PhD in Neurosciences from INSERM, Paris, and a PhD in Medicine from the University of Pavia, Italy.

Corporate Governance Overview

The Board of Directors of ONWARD Medical (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations. They are effective as of first day of trading.